Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Champions Biotechnology, Pharmaceutical Industries sign Master Service Agreement

Champions Biotechnology, Inc., an oncology drug development company with a predictive translational platform aimed at accelerating the development and enhancing the value of oncology drugs, announced that a Master Service Agreement with Teva Pharmaceutical Industries has been commissioned for the testing of a novel anti-angiogenic compound in the Champions Tumorgraft™ platform.

7 Dec 2010

Preclinical data of ZIO-101 in various lymphoma models presented at ASH 2010

ZIOPHARM Oncology, Inc. announced today that new preclinical data on the novel mechanism of its organic arsenic darinaparsin (ZIO-101) in various lymphoma models were presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology in Orlando Florida.

6 Dec 2010

Asuragen, Novartis to develop ARQ BCR-ABL1 RNA IS Calibrators, laboratory software reporting tools

Asuragen, Inc. announced today that it has entered into an exclusive agreement with Novartis to develop worldwide Armored RNA Quant BCR-ABL1 RNA International Scale Calibrators and laboratory software reporting tools, intended to aid laboratories with standardization of BCR-ABL1 RT-qPCR testing to the International Scale. As part of this agreement, Asuragen will develop and, if successful, distribute the ARQ BCR-ABL1 IS RNA Calibrators and software reporting tools to laboratories globally directly or through its distributors.

6 Dec 2010

Elsevier announces title change for Cancer Genetics and Cytogenetics journal

Elsevier, the world's leading publisher of scientific, technical and medical information, announced today that its highly respected Cancer Genetics and Cytogenetics journal is changing its title to Cancer Genetics and has named Dr. Jaclyn A. Biegel as editor-in-chief.

6 Dec 2010

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

Telik, Inc. today announced positive results from a Phase 2 multicenter trial of oral ezatiostat hydrochloride (TELINTRA, TLK199) in patients with an International Prognostic System Score of low to intermediate-1 risk myelodysplastic syndrome.

6 Dec 2010

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies. Research that will be presented today at the 52nd Annual Meeting of the American Society of Hematology provides greater understanding of the optimal use of several BCR-ABL inhibitors for the treatment of acute lymphoblastic leukemia and chronic myeloid leukemia, and how a new gene target functions for several myeloid malignancies.

6 Dec 2010

Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010

Portola Pharmaceuticals, Inc. today announced the presentation of preclinical study results for its novel Syk and JAK inhibitor program at the American Society of Hematology's 52nd Annual Meeting and Exposition. Portola's novel Syk and JAK inhibitors are in development to treat chronic inflammatory diseases, including rheumatoid arthritis, and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

6 Dec 2010

Cell Therapeutics announces new pixantrone EOS follow up results

Cell Therapeutics, Inc. today announced new pixantrone end of study follow up results from the Company's pivotal phase III PIX301 trial, which results form the basis for the Company's recent Marketing Authorization Application currently under review by the European Medicines Agency.

6 Dec 2010

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today the presentation of new preclinical data for CYC065, a novel, orally-available, cell cycle kinase inhibitor. The data were reported at a poster presentation at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.

6 Dec 2010

BioCryst reports Phase 2 trial data of forodesine in patients with CLL

BioCryst Pharmaceuticals, Inc. announced the presentation of new data that confirms forodesine's clinical activity in the treatment of chronic lymphocytic leukemia at the 52nd Annual American Society of Hematology Meeting & Exposition being held in Orlando, Florida.

6 Dec 2010

$Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010$

Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive results from the pivotal trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate targeted to CD30, a defining marker of Hodgkin lymphoma.

6 Dec 2010

Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting

Pharmacyclics, Inc. today announced data from three Chronic Lymphocytic Leukemia presentations at the American Society of Hematology Annual Meeting describing the Btk-selective inhibitor PCI-32765. Two presentations report preclinical data, and one presentation reports clinical data from a pooled analysis of 54 patients with CLL or Small Lymphocytic Lymphoma treated with PCI-32765.

6 Dec 2010

Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting

Cyclacel Pharmaceuticals, Inc. announced today 1-year survival data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes refractory to hypomethylating agents, such as azacitidine and decitabine. The data were reported at a poster presentation at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.

6 Dec 2010

$Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting$

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Allos Therapeutics, Inc. today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting held in Orlando, Florida.

6 Dec 2010

Seven studies on Oncotype DX breast cancer test to be presented at 33rd CTRC-AACR SABCS

Genomic Health, Inc. today announced that the company will present results from seven studies at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), taking place December 8-12, 2010 at the Henry B. Gonzalez Convention Center.

4 Dec 2010

Clinical studies participated by three investigators to be presented at ASH Annual Meeting and Exposition

US Oncology, Inc., the nation's leading integrated oncology company, announced today that three investigators affiliated with US Oncology Research participated in studies that will be presented orally at the 52nd American Society of Hematology Annual Meeting and Exposition at the Orange County Convention Center in Orlando, Fla. Dec. 4-7. Five other investigators in the US Oncology Research Network participated in a study that will be displayed as a poster during the conference.

4 Dec 2010

Access adds patient experience testimonial video to MuGard website

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has updated its lead product website, www.MuGard.com, with its first patient MuGard experience testimonial video and additional clinician feedback.

4 Dec 2010

Pfizer plans regulatory submissions of bosutinib for CML based on BELA study

Pfizer Inc. announced today it is planning regulatory submissions of bosutinib in patients with chronic myeloid leukemia (CML) based on data from a clinical program evaluating the compound in newly diagnosed and previously treated patients. These regulatory submissions are planned for 2011.

4 Dec 2010

New web-based CME program to improve cancer care in rural areas

Nearly a quarter of Americans live in rural areas, which consistently report higher cancer mortality rates than urban and suburban areas. Among the complex causes for this disparity is that only 10 percent of physicians practice in rural areas and almost 4 out of 10 rural residents live at least an hour from an urban area. Finding the time, transportation, and financial resources for travel to urban academic medical centers, the standard bearers for quality cancer care, often proves difficult.

4 Dec 2010

Onconova announces three presentations on Estybon- (ON 01910.Na) at ASH 2010

Onconova Therapeutics announces its late-stage anticancer agent, Estybon- (ON 01910.Na), will be featured in three presentations at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL, December 4-7, 2010.

4 Dec 2010

Oncology News and Research

Further Reading

Champions Biotechnology, Pharmaceutical Industries sign Master Service Agreement

Preclinical data of ZIO-101 in various lymphoma models presented at ASH 2010

Asuragen, Novartis to develop ARQ BCR-ABL1 RNA IS Calibrators, laboratory software reporting tools

Elsevier announces title change for Cancer Genetics and Cytogenetics journal

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010

Cell Therapeutics announces new pixantrone EOS follow up results

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

BioCryst reports Phase 2 trial data of forodesine in patients with CLL

Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010

Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting

Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Seven studies on Oncotype DX breast cancer test to be presented at 33rd CTRC-AACR SABCS

Clinical studies participated by three investigators to be presented at ASH Annual Meeting and Exposition

Access adds patient experience testimonial video to MuGard website

Pfizer plans regulatory submissions of bosutinib for CML based on BELA study

New web-based CME program to improve cancer care in rural areas

Onconova announces three presentations on Estybon- (ON 01910.Na) at ASH 2010

eBook: Liquid biopsy in cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News